
Guardant Health (GH) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
203.5M
Gross Profit
128.7M
63.28%
Operating Income
-111.0M
-54.57%
Net Income
-95.2M
-46.77%
EPS (Diluted)
$-0.77
Balance Sheet Metrics
Total Assets
1.3B
Total Liabilities
1.6B
Shareholders Equity
-250.8M
Cash Flow Metrics
Operating Cash Flow
-49.4M
Free Cash Flow
-67.1M
Revenue & Profitability Trend
Guardant Health Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 739.0M | 563.9M | 449.5M | 373.7M | 286.7M |
Cost of Goods Sold | 289.8M | 227.1M | 156.3M | 122.9M | 92.5M |
Gross Profit | 449.2M | 336.9M | 293.2M | 250.7M | 194.2M |
Gross Margin % | 60.8% | 59.7% | 65.2% | 67.1% | 67.7% |
Operating Expenses | |||||
Research & Development | 347.8M | 367.2M | 373.8M | 263.2M | 149.9M |
Selling, General & Administrative | 545.1M | 451.0M | 463.8M | 398.5M | 299.3M |
Other Operating Expenses | - | 83.4M | - | - | - |
Total Operating Expenses | 892.8M | 901.6M | 837.6M | 661.7M | 449.1M |
Operating Income | -443.6M | -564.7M | -544.4M | -411.0M | -255.0M |
Operating Margin % | -60.0% | -100.1% | -121.1% | -110.0% | -88.9% |
Non-Operating Items | |||||
Interest Income | 53.7M | 35.4M | 6.1M | 3.9M | 10.2M |
Interest Expense | 2.6M | 2.6M | 2.6M | 2.6M | 4.8M |
Other Non-Operating Income | -42.6M | 53.2M | -112.6M | 25.2M | 3.6M |
Pre-tax Income | -435.1M | -478.8M | -653.4M | -384.5M | -245.9M |
Income Tax | 1.3M | 685.0K | 1.1M | 300.0K | 379.0K |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -436.4M | -479.4M | -654.6M | -384.8M | -246.3M |
Net Margin % | -59.0% | -85.0% | -145.6% | -103.0% | -85.9% |
Key Metrics | |||||
EBITDA | -390.1M | -433.3M | -614.9M | -359.6M | -225.1M |
EPS (Basic) | $-3.56 | $-4.28 | $-6.41 | $-4.00 | $-2.60 |
EPS (Diluted) | $-3.56 | $-4.28 | $-6.41 | $-4.00 | $-2.60 |
Basic Shares Outstanding | 122745000 | 111988000 | 102178000 | 101314000 | 97504000 |
Diluted Shares Outstanding | 122745000 | 111988000 | 102178000 | 101314000 | 97504000 |
Income Statement Trend
Guardant Health Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 525.5M | 1.1B | 141.6M | 492.2M | 833.0M |
Short-term Investments | 314.4M | 35.1M | 869.6M | 440.5M | 961.9M |
Accounts Receivable | 106.9M | 88.8M | 97.3M | 97.7M | 53.3M |
Inventory | 71.1M | 61.9M | 51.6M | 30.7M | 22.7M |
Other Current Assets | 33.8M | 27.7M | 31.5M | 53.1M | - |
Total Current Assets | 1.1B | 1.3B | 1.2B | 1.1B | 1.9B |
Non-Current Assets | |||||
Property, Plant & Equipment | 142.3M | 157.6M | 174.0M | 189.4M | 37.3M |
Goodwill | 13.3M | 15.6M | 18.3M | 20.8M | 22.7M |
Intangible Assets | 6.8M | 9.0M | 11.7M | 14.2M | 16.2M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 141.4M | 124.3M | 61.5M | 60.9M | 17.3M |
Total Non-Current Assets | 430.5M | 439.3M | 418.4M | 1.1B | 383.4M |
Total Assets | 1.5B | 1.8B | 1.6B | 2.2B | 2.3B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 38.6M | 51.7M | 68.9M | 38.5M | 7.3M |
Short-term Debt | 29.2M | 28.0M | 21.9M | 12.9M | 6.6M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | 78.0M | - |
Total Current Liabilities | 225.6M | 205.9M | 193.2M | 194.7M | 66.8M |
Non-Current Liabilities | |||||
Long-term Debt | 1.3B | 1.3B | 1.3B | 1.4B | 847.9M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 92.8M | 96.0M | 9.2M | 3.9M | 1.5M |
Total Non-Current Liabilities | 1.4B | 1.4B | 1.4B | 1.4B | 849.4M |
Total Liabilities | 1.6B | 1.6B | 1.5B | 1.6B | 916.2M |
Equity | |||||
Common Stock | 1.0K | 1.0K | 1.0K | 1.0K | 1.0K |
Retained Earnings | -2.6B | -2.1B | -1.7B | -1.0B | -606.6M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | -139.6M | 158.7M | 60.2M | 645.0M | 1.4B |
Key Metrics | |||||
Total Debt | 1.3B | 1.4B | 1.4B | 1.4B | 854.5M |
Working Capital | 829.5M | 1.1B | 998.4M | 919.4M | 1.8B |
Balance Sheet Composition
Guardant Health Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -436.4M | -479.4M | -654.6M | -384.8M | -246.3M |
Depreciation & Amortization | 42.4M | 42.9M | 36.0M | 22.3M | 16.1M |
Stock-Based Compensation | 140.4M | 90.8M | 94.7M | 151.4M | 144.1M |
Working Capital Changes | -50.4M | -30.4M | 41.1M | -30.9M | -40.2M |
Operating Cash Flow | -267.0M | -345.0M | -347.6M | -212.3M | -107.7M |
Investing Activities | |||||
Capital Expenditures | -35.1M | -20.5M | -77.5M | -75.0M | -36.2M |
Acquisitions | - | - | - | 0 | 0 |
Investment Purchases | -314.8M | -635.5M | -327.7M | -940.2M | -1.1B |
Investment Sales | 88.6M | 1.5B | 555.0M | 952.1M | 562.5M |
Investing Cash Flow | -261.3M | 840.2M | 149.8M | -63.2M | -599.2M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | 0 | 0 | 1.1B |
Debt Repayment | - | - | -71.0K | -146.0K | -174.0K |
Financing Cash Flow | -15.8M | 466.8M | -201.1M | -84.8M | 1.4B |
Free Cash Flow | -274.9M | -345.5M | -386.9M | -284.1M | -158.0M |
Net Change in Cash | -544.1M | 962.0M | -398.8M | -360.3M | 686.8M |
Cash Flow Trend
Guardant Health Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-16.54
Forward P/E
-21.73
Price to Book
-23.92
Price to Sales
8.86
PEG Ratio
3.47
Profitability Ratios
Profit Margin
-49.93%
Operating Margin
-45.75%
Return on Equity
312.48%
Return on Assets
-19.57%
Financial Health
Current Ratio
3.70
Debt to Equity
-4.37
Beta
1.44
Per Share Data
EPS (TTM)
$-3.35
Book Value per Share
$-2.45
Revenue per Share
$6.70
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
gh | 7.3B | -16.54 | -23.92 | 312.48% | -49.93% | -4.37 |
Thermo Fisher | 184.7B | 28.25 | 3.66 | 13.42% | 15.24% | 69.62 |
Danaher | 151.0B | 44.88 | 2.89 | 6.68% | 14.21% | 35.45 |
Exact Sciences | 8.6B | -8.16 | 3.49 | -35.51% | -34.19% | 102.73 |
Charles River | 7.7B | 681.33 | 2.30 | -1.81% | -1.66% | 82.04 |
RadNet | 5.2B | 1,425.75 | 5.43 | 1.74% | -0.78% | 156.12 |
Financial data is updated regularly. All figures are in the company's reporting currency.